Mesothelioma  >>  Opdivo (nivolumab)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Opdivo (nivolumab) / BMS
MESOIMMUNE, NCT04775446: Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy

Completed
N/A
116
Europe
Data collection
Centre Hospitalier Intercommunal Creteil
Malignant Pleural Mesothelioma
10/21
10/21
MESO-IMMUNE, NCT05308966: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab

Active, not recruiting
N/A
200
Europe
Data collection
Groupe Francais De Pneumo-Cancerologie, Bristol-Myers Squibb
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
04/25
04/25

Download Options